Literature DB >> 28039541

Patient-reported outcomes in Asia: evaluation of the properties of the Rheumatoid Arthritis Impact of Disease (RAID) score in multiethnic Asian patients with rheumatoid arthritis.

Peter P Cheung1,2, Manjari Lahiri3,4, Lyn March5, Laure Gossec6,7.   

Abstract

Patient-reported outcomes (PROs) such as the Europe-developed Rheumatoid Arthritis Impact of Disease (RAID) are important to assess patients' quality of life. Their interpretation may be culture-dependent. To evaluate the potential utility of RAID in multiethnic Asian rheumatoid arthritis (RA) patients. Cross-sectional study of English-speaking RA patients in a Singapore tertiary center. Validity of RAID (scored between 0 and 10 with higher score indicating worse status) was assessed by Spearman's correlation with patient global assessment (PGA), DAS28 and short form 12 (SF-12). Consistency was assessed by Cronbach's alpha and test-retest reliability by intra-class correlation coefficient (ICC) 7 days after (n = 20). Feasibility was assessed by % of missing data. Eighty-two patients were analyzed: median age 53 years (Q1:Q3 44.7; 60.7), disease duration 4.2 years (1.4; 8.8), 66 (81%) women and 54 (66%) Chinese. Although RA was moderately active (median DAS28, 3.2 (2.5; 4.3)), RAID score was very low (median, 1.9 (0.6; 3.7)) with 44 (53.7%) patients having RAID score between 0 and 2. RAID was strongly correlated with PGA (r = 0.75), and moderately with other outcomes (DAS28 r = 0.46, SF12 physical r = -0.45 and SF12 mental r = -0.52, p < 0.0001 for all). Consistency was high (Cronbach's alpha = 0.91). Test-retest reliability was excellent; ICC = 0.84 (95% confidence interval 0.74-0.90). Feasibility was good with only 2 patients with missing data. Despite considerable floor effects, the RAID appeared to be a valid and practical PRO to assess the impact of RA in Asia. Multiethnic Asian patients may underestimate the impact of their disease compared to European patients.

Entities:  

Keywords:  Asia; Burden of disease; EULAR; Patient-reported outcome; Rheumatoid arthritis

Mesh:

Year:  2016        PMID: 28039541     DOI: 10.1007/s10067-016-3522-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study.

Authors:  Polina Putrik; Sofia Ramiro; Monika Hifinger; Andras P Keszei; Ihsane Hmamouchi; Maxime Dougados; Laure Gossec; Annelies Boonen
Journal:  Ann Rheum Dis       Date:  2015-08-27       Impact factor: 19.103

Review 2.  Patient reported outcomes in rheumatoid arthritis clinical trials.

Authors:  Ana-Maria Orbai; Clifton O Bingham
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

Review 3.  Patient-reported outcomes in rheumatoid arthritis.

Authors:  Minyoung Her; Arthur Kavanaugh
Journal:  Curr Opin Rheumatol       Date:  2012-05       Impact factor: 5.006

4.  A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the RAEUS Study.

Authors:  Peter P Cheung; Manjari Lahiri; Gim Gee Teng; Anita Y N Lim; Tang Ching Lau; Aisha Lateef; Anselm Mak; Laure Gossec; Lyn March
Journal:  Rheumatology (Oxford)       Date:  2014-12-03       Impact factor: 7.580

5.  Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative.

Authors:  L Gossec; M Dougados; N Rincheval; A Balanescu; D T Boumpas; S Canadelo; L Carmona; J-P Daurès; M de Wit; B A C Dijkmans; M Englbrecht; Z Gunendi; T Heiberg; J R Kirwan; E M Mola; M Matucci-Cerinic; K Otsa; G Schett; T Sokka; G A Wells; G J Aanerud; A Celano; A Dudkin; C Hernandez; K Koutsogianni; F N Akca; A-M Petre; P Richards; M Scholte-Voshaar; G Von Krause; T K Kvien
Journal:  Ann Rheum Dis       Date:  2008-12-03       Impact factor: 19.103

6.  Health-related quality of life and its predictors among patients with rheumatoid arthritis.

Authors:  Su Wei Wan; Hong-Gu He; Anselm Mak; Manjari Lahiri; Nan Luo; Peter P Cheung; Wenru Wang
Journal:  Appl Nurs Res       Date:  2015-08-03       Impact factor: 2.257

7.  Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID).

Authors:  Maxime Dougados; Yves Brault; Isabelle Logeart; Désirée van der Heijde; Laure Gossec; Tore Kvien
Journal:  Arthritis Res Ther       Date:  2012-05-30       Impact factor: 5.156

8.  Patient Acceptable Symptom State in Self-Report Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care.

Authors:  Fausto Salaffi; Marina Carotti; Marwin Gutierrez; Marco Di Carlo; Rossella De Angelis
Journal:  Biomed Res Int       Date:  2015-06-18       Impact factor: 3.411

Review 9.  Reporting of patient-perceived impact of rheumatoid arthritis and axial spondyloarthritis over 10 years: a systematic literature review.

Authors:  Laure Gossec; Francis Berenbaum; Pierre Chauvin; Karine Lamiraud; Francoise Russo-Marie; Jean-Michel Joubert; Alain Saraux
Journal:  Rheumatology (Oxford)       Date:  2014-03-06       Impact factor: 7.580

Review 10.  Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis.

Authors:  Laure Gossec; Maxime Dougados; William Dixon
Journal:  RMD Open       Date:  2015-04-02
View more
  4 in total

1.  Clinical performance of rheumatoid arthritis impact of disease score: a real-life evidence from the multicenter nationwide registry BioStaR.

Authors:  Meltem Alkan Melikoglu; Sebnem Ataman; Hatice Bodur; Hasan Fatih Cay; Erhan Capkin; Ozgur Akgul; Remzi Cevik; Feride Gogus; Ayhan Kamanli; Fatma Gul Yurdakul; Gulcan Gurer; Ilker Yagci; Aylin Rezvani; Mehmet Tuncay Duruoz; Ismihan Sunar
Journal:  Rheumatol Int       Date:  2021-09-24       Impact factor: 2.631

2.  Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National Database.

Authors:  Katja Thiele; Katinka Albrecht; Angela Zink; Martin Aringer; Kirsten Karberg; Susanna Späthling-Mestekemper; Ulrich von Hinüber; Johanna Callhoff
Journal:  RMD Open       Date:  2022-07

3.  Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients.

Authors:  Jose Antonio Pereira da Silva; Laure Gossec; Catia Duarte; Eduardo José Ferreira Santos; Ricardo J O Ferreira; Tore K Kvien; Maxime Dougados; Maarten de Wit
Journal:  RMD Open       Date:  2021-02

4.  Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study.

Authors:  Yue Yang; Jianhua Xu; Jian Xu; Xingfu Li; Jiankang Hu; Xiangpei Li; Xiao Zhang; Dongyi He; Chunde Bao; Zhijun Li; Guochun Wang; Cristiano A F Zerbini; Alberto J Spindler; Carol L Kannowski; Hanjun Wu; Fei Ji; Lujing Zhan; Mengru Liu; Zhanguo Li
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-04-20       Impact factor: 5.346

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.